Mikhail Blagosklonny, a prominent researcher in anti-aging and oncology treatment procedures, is making headlines with his hyperfunction theory that is paving ways for the development of anti-aging drugs. Based on the theory, various research institutes and pharmaceutical firms are trying to advance in the development of the treatment of regime. The theory states that aging is to be considered as a continuation of growth paving ways to Target of Rapamycin or TOR. It was believed that aging was due to the functional decline of random molecular damages and deduced it cannot be stopped.
Since Blagosklonny put forward the theory in the early 2000s, there were researches based on that, and even few rapamycin analogs such as Everolimus introduced into the market and showed the improvements in immunity of older people. The treatment procedure started in the year 2008, and it is almost a decade now with significant outputs in the health of humans. Blagosklonny did an overall review of the changes the rapamycin analogs and other anti-aging drugs make in the human body. The TOR-centric model proposed in 2008 that rapamycin analogs can prevent diseases and increase the healthy lifespan of human beings. Today, more companies are in the race to produce quality “youth drugs” which can target anti-aging.
Now it is proved that by slowing the aging using calorie restriction and rapamycin, people can reduce the aging and diseases such as cancer. As it concluded that aging is a part of growth, it is also found that growth-promoting signaling in the human body in the initial years are becoming harmful for the body at the later point of time. The gerontologists state the importance of anti-oxidants and free radicals in aging, and hyperfunction theory says the importance of anti-aging drugs such as metformin and rapamycin. Visit ResearchGate to keep up to date with Mikhail’s latest work.
Blagosklonny is a professor of Roswell Park Cancer Institute with the research focus on cancer and aging. His deep expertise in cancer research and teaching has helped him to make significant results in achieving his goal of a world without disease. Mikhail Blagosklonny started his career with New York Medical College in 2002 as an associate professor. By keeping research in mind, he later joined Ordway Research Institute as a senior scientist and played crucial roles in developing targeted treatment regime for the cancer patients by avoiding the damage of healthy cells.
Blagosklonny collaborates with a number of science journals in various positions. He is the editor-in-chief of Cell Cycle. Mikhail is the associate editor of the American Journal of Pathology, Cancer Biology and Therapy, International Journal of Cancer, and PLOS ONE. He is also on the editorial board of the Cell Death and Differentiation. Until the date, Blagosklonny published more than 300 papers, research articles, reviews, and book chapters. He completed his Master of Doctorate in Internal Medicine from First Pavlov State Medical University. Mikhail continued his studies there and also secured his Ph.D. in Cardiology and Experimental Medicine.